ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2010
Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma.Heliyon · 2023Article
- Lumican in Carcinogenesis-Revisited.Biomolecules · 2021Review
- Proteomic Signature of Dysfunctional Circulating Endothelial Colony-Forming Cells of Young Adults.Journal of the American Heart Association · 2021Article
- Label-Free Infrared Spectral Histology of Skin Tissue Part II: Impact of a Lumican-Derived Peptide on Melanoma Growth.Frontiers in cell and developmental biology · 2020Article
- Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks.Frontiers in oncology · 2019Review
- Small Leucine-Rich Proteoglycans in Skin Wound Healing.Frontiers in pharmacology · 2019Review
- Hypoxia-Induced Autophagy Degrades Stromal Lumican into Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma: A Mini-Review.Journal of cancer treatment & diagnosis · 2019Article
- Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth.Oncogene · 2017Article
- Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide.Scientific reports · 2017Article
- Lumican negatively controls the pathogenicity of murine encephalitic TH17 cells.European journal of immunology · 2016Article
- Extracellular Matrix, a Hard Player in Angiogenesis.International journal of molecular sciences · 2016Review
- Skin rejuvenation using cosmetic products containing growth factors, cytokines, and matrikines: a review of the literature.Clinical, cosmetic and investigational dermatology · 2016Review
- Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Lumican exhibits anti-angiogenic activity in a context specific manner.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013Article
- Lumican expression, localization and antitumor activity in prostate cancer.Experimental cell research · 2013Article
- Matrix Gla protein reinforces angiogenic resolution.Microvascular research · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Matrikines are important components of tumor microenvironments that integrate communication between extracellular matricies and membrane-bound receptors thereby regulating cellular behaviors. One such matrikine that is differentially expressed in cancer microenvironments is the extracellular matrix protein lumican; however its precise role in cancer remains ambiguous. To study the effects of lumican on cancer cells, we created lumican-overexpressing cell lines from murine fibrosarcoma (MCA102) and pancreatic adenocarcinoma (Pan02) cells. Lumican overexpression in Pan02 cells increased invasiveness, decreased soft agar colony size, and increased proliferation. Conversely in MCA102 cells, lumican decreased invasiveness, increased soft agar colony size, but did not influence proliferation. In contrast to these pleiotropic in vitro results, lumican overexpression within the in vivo tumor microenvironment produced uniformly smaller tumors. Importantly, reduced tumor size was correlated with reduced vascular density. Consistent with lumican's proposed anti-angiogenic activity, lumican increased endothelial cell apoptosis. Importantly, lumican was previously shown to influence Fas expression and our results show that lumican enhanced Fas mediated endothelial cell apoptosis although we were unable to detect any difference in Fas or Fas ligand expression between lumican-overexpressing and control cells. Interestingly, lumican had no effect on MCA102 apoptosis, suggesting that the observed reduction in tumor size is specifically due to endothelial cell apoptosis rather than a direct effect on the cancerous cells themselves. Therefore, this study is the first to demonstrate a causal relationship between tumor reduction and lumican's effect on angiogenesis as opposed to an effect on the cancerous cells themselves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.